Dr. Shan Luo is a researcher specializing in the study of non-communicable diseases and the validation, safety, and repositioning of drug targets. Using cutting-edge techniques such as genetic epidemiology, Mendelian randomization, and multi-omics approaches, she aims to address critical pharmacological intervention needs. Dr. Luo’s work includes the identification of novel drug targets for rare diseases, such as juvenile idiopathic arthritis, the evaluation of drug safety in pediatric populations, and the repositioning of drug targets like metformin to promote healthy longevity.
Early bird registration is open and closes May 2025. Register now
